Warner Chilcott’s Q2 Revenue Increases 7.1%

Warner Chilcott’s revenue in the quarter ended June 30, 2009 increased 7.1% to $250.8m over the prior year quarter.

The company reported net income of $56m, or $0.22 per diluted share in the quarter ended June 30, 2009, compared to net income of $33.6m, or $0.13 per diluted share in the prior year quarter, an increase of 66.9%. For the six month ended period, the company recorded a net income of $99.3m, compared to $67.2m for the same period an year ago.

In the product segments, net sales for oral contraceptive products increased $4.2m, or 5.6%, in the quarter ended June 30, 2009, compared to the prior year quarter. Net sales for dermatology products increased $11.3 million, or 10.9%, whereas net sales for hormone therapy products increased $3.9 million, or 9.1%.

Warner Chilcott is a specialty pharmaceutical company currently focused on the women’s healthcare and dermatology segments of the US pharmaceuticals market. The company is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products.